Table 2.
Univariate and multivariate associations of EGFR mutation and FISH status, clinicopathological characteristics, and status of other seven genes with PFS and OS in the total of 416 NSCLC patients
| Variable | PFS | OS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||||||
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Age | ||||||||||||
| ≤ 60 | 1 | 1 | ||||||||||
| > 60 | 1.01 | 0.82–1.25 | 0.913 | 1.21 | 0.94–1.57 | 0.145 | ||||||
| Gender | ||||||||||||
| Male | 1 | 1 | 1 | 1 | ||||||||
| Female | 0.59 | 0.48–0.73 | < 0.001 | 0.56 | 0.42–0.74 | < 0.001 | 0.59 | 0.45–0.76 | < 0.001 | 0.65 | 0.48–0.94 | 0.006 |
| Smoking status | ||||||||||||
| Smoking | 1 | 1 | 1 | 1 | ||||||||
| No smoking | 0.60 | 0.48–0.74 | < 0.001 | 0.64 | 0.50–0.81 | < 0.001 | 0.62 | 0.48–0.80 | < 0.001 | 0.79 | 0.58–1.06 | 0.113 |
| Histology | ||||||||||||
| Non-ADC | 1 | 1 | 1 | |||||||||
| ADC | 0.67 | 0.52–0.86 | 0.002 | 0.84 | 0.64–1.10 | 0.203 | 0.78 | 0.58–1.07 | 0.122 | |||
| Differentiation | ||||||||||||
| High to medium | 1 | 1 | 1 | |||||||||
| Low | 1.36 | 1.11–1.68 | 0.004 | 0.89 | 0.72–1.18 | 0.299 | 1.12 | 0.87–1.44 | 0.363 | |||
| Stage | ||||||||||||
| Recurrent | 1 | 1 | ||||||||||
| IIIB and IV | 0.88 | 0.70–1.10 | 0.254 | 0.83 | 0.63–1.09 | 0.183 | ||||||
| Line of TKI therapy | ||||||||||||
| 2, 3 | 1 | 1 | 1 | 1 | ||||||||
| 1 | 0.68 | 0.53–0.87 | 0.002 | 0.75 | 0.58–0.97 | 0.027 | 0.67 | 0.50–0.90 | 0.009 | 0.78 | 0.57–1.05 | 0.103 |
| ECOG PS | ||||||||||||
| 2 | 1 | 1 | 1 | 1 | ||||||||
| 0, 1 | 0.71 | 0.52–0.95 | 0.023 | 0.73 | 0.54–0.99 | 0.043 | 1.71 | 1.17–2.48 | 0.004 | 0.62 | 0.43–0.90 | 0.011 |
| EGFR mutation | ||||||||||||
| Mt | 1 | 1 | 1 | 1 | ||||||||
| Wt | 0.38 | 0.31–0.47 | < 0.001 | 0.54 | 0.42–0.70 | < 0.001 | 0.50 | 0.38–0.65 | < 0.001 | 0.63 | 0.47–0.85 | 0.002 |
| EGFR copy number | ||||||||||||
| FISH− | 1 | 1 | 1 | 1 | ||||||||
| FISH+ | 0.54 | 0.43–0.67 | < 0.001 | 0.67 | 0.54–0.84 | 0.001 | 0.60 | 0.46–0.78 | < 0.001 | 0.77 | 0.58–1.02 | 0.068 |
| ALK | ||||||||||||
| Wt | 1 | 1 | 1 | 1 | ||||||||
| Apart | 2.06 | 1.41–3.02 | < 0.001 | 1.41 | 0.93–2.16 | 0.105 | 1.59 | 1.00–2.51 | 0.047 | 1.34 | 0.82–2.17 | 0.240 |
| BIM | ||||||||||||
| Wt | 1 | 1 | ||||||||||
| Deletion | 0.89 | 0.58–1.36 | 0.596 | 1.05 | 0.64–1.71 | 0.856 | ||||||
| KRAS mutation | ||||||||||||
| Wt | 1 | 1 | 1 | |||||||||
| Mt | 1.99 | 1.33–2.99 | 0.001 | 1.21 | 0.79–1.84 | 0.386 | 1.55 | 0.97–2.47 | 0.070 | |||
| PIK3CA mutation | ||||||||||||
| wt | 1 | 1 | ||||||||||
| mt | 1.18 | 0.61–2.29 | 0.619 | 1.22 | 0.60–2.47 | 0.583 | ||||||
| PTEN copy number | ||||||||||||
| Intact | 1 | 1 | ||||||||||
| Deletion | 1.54 | 0.99–2.39 | 0.058 | 1.06 | 0.64–1.77 | 0.811 | ||||||
| PTEN expression | ||||||||||||
| Normal | 1 | 1 | 1 | |||||||||
| Low expression | 1.37 | 1.08–1.74 | 0.011 | 1.10 | 0.86–1.42 | 0.439 | 1.12 | 0.84–1.50 | 0.448 | |||
| MET copy number | ||||||||||||
| FISH− | 1 | 1 | 1 | 1 | ||||||||
| FISH+ | 1.87 | 1.35–2.60 | < 0.001 | 1.51 | 1.07–2.13 | 0.019 | 1.64 | 1.14–2.37 | 0.008 | 1.47 | 1.01–2.13 | 0.045 |
| MET expression | ||||||||||||
| MAb− | 1 | 1 | ||||||||||
| MAb+ | 1.01 | 0.79–1.28 | 0.955 | 1.18 | 0.87–1.59 | 0.283 | ||||||
| MET expression | ||||||||||||
| H-score− | 1 | 1 | ||||||||||
| H-score+ | 1.14 | 0.93–1.40 | 0.217 | 0.97 | 0.75–1.25 | 0.805 | ||||||
| IGF1R copy number | ||||||||||||
| FISH− | 1 | 1 | 1 | |||||||||
| FISH+ | 1.40 | 1.05–1.87 | 0.019 | 1.07 | 0.78–1.46 | 0.688 | 1.10 | 0.77–1.57 | 0.619 | |||
| IGF1R expression | ||||||||||||
| IHC− | 1 | 1 | ||||||||||
| IHC+ | 1.26 | 0.99–1.61 | 0.062 | 1.05 | 0.78–1.40 | 0.770 | ||||||
ADC adenocarcinoma, ECOG Eastern cooperative oncology group, TKI tyrosine kinase inhibitors, FISH fluorescent in situ hybridization, HR hazard ratio, CI confidence interval, PFS progression-free survival, OS overall survival